(Q34487151)

2 August 2017

title

Optimizing cellular immunity against HIV-1 Gag and preventing suppression by HIV-1 gp120. (English)

1 reference

2 August 2017

2

Rogier W Sanders

1 reference

2 August 2017

Thijs van Montfort

1

1 reference

2 August 2017

publication date

1 October 2012

1 reference

Expert Review of Vaccines

2 August 2017

published in

1 reference

2 August 2017

volume

11

1 reference

2 August 2017

issue

10

1 reference

2 August 2017

page(s)

1175-1177

1 reference

Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.102

21 January 2018

Identifiers

DOI

10.1586/ERV.12.102

1 reference

2 August 2017

1 reference